Published in Blood Weekly, October 11th, 1999
K.A. Margolin and colleagues, City of Hope National Medical Center, California, conducted a pilot trial of interleukin (IL)-2-treated autologous bone marrow (BM) and peripheral stem cell (PSC)-supported high-dose chemoradiotherapy ("Interleukin-2-Activated Autologous Bone Marrow and Peripheral Blood Stem Cells in the Treatment of Acute Leukemia and Lymphoma," Biol Blood Marrow Transplant 1999;5(1):36-45).
They reported on 36 patients with poor-prognosis leukemia and lymphoma who received BM and/or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.